Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Vertex Pharmaceuticals Incorporated < Previous 1 2 3 4 Next > Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes March 09, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7 February 21, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Fourth Quarter and Full Year Financial 2022 Results February 07, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7 January 17, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9 January 04, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA December 12, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition December 10, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) December 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers TRDA VRTX Vertex to Participate in Upcoming Investor Conferences November 09, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD) November 04, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference November 03, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Third Quarter 2022 Financial Results October 27, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Third Quarter 2022 Financial Results on October 27 October 13, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency October 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 September 27, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Appoints Jonathan Biller as Chief Legal Officer September 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months September 02, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9 August 31, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Reports Second Quarter 2022 Financial Results August 04, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Advances VX-548 in Acute and Neuropathic Pain July 22, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Announce Second Quarter 2022 Financial Results on August 4 July 18, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes July 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes July 05, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress June 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference June 10, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 June 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA June 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions June 06, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress June 02, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers CRSP VRTX Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference May 31, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Tickers VRTX < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.